AnnJi Pharmaceutical Co., Ltd. (TPEX:7754)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
51.90
+1.10 (2.17%)
Feb 11, 2026, 1:59 PM CST
Market Cap4.77B +50.6%
Revenue (ttm)23.85M -86.9%
Net Income-317.13M
EPS-3.38
Shares Out93.88M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume304,290
Average Volume257,348
Open51.60
Previous Close50.80
Day's Range50.90 - 52.20
52-Week Range14.05 - 58.00
Betan/a
RSI53.98
Earnings DateMar 25, 2026

About AnnJi Pharmaceutical

AnnJi Pharmaceutical Co., Ltd. develops drugs in the therapeutic areas of neurology, dermatology, and inflammatory disorders. It develops therapeutics, such as AJ201 for the treatment of spinal and bulbar muscular atrophy disease; AJ302, a histone deacetylase 6 inhibitor for the prevention and treatment of chemotherapy-induced peripheral neuropathy; and AJ303, an anti-fibrotic and anti-inflammatory compound for the treatment of idiopathic pulmonary fibrosis diseases. AnnJi Pharmaceutical Co., Ltd. was founded in 2014 and is based in Taipei, Tai... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 7754
Full Company Profile

Financial Performance

In 2024, AnnJi Pharmaceutical's revenue was 96.45 million, a decrease of -32.80% compared to the previous year's 143.53 million. Losses were -353.99 million, 7.52% more than in 2023.

Financial Statements